Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 6/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6213121 | 0.91 | MMP13 (0.49) | MMP13PPARGMAPTRXFP1EPHX2 | |
| SCHEMBL6212954 | 0.89 | MMP13 (0.60) | MMP13PPARGPTGER4MAPTRXFP1 | |
| SCHEMBL6211147 | 0.85 | TDP1 (0.43) | MMP13PPARGMAPTRORCRXFP1 | |
| SCHEMBL6212605 | 0.85 | PIK3CA (0.46) | MMP13MAPTRXFP1KDM4EKDR | |
| SCHEMBL6211828 | 0.85 | PPARG (0.52) | MMP13PPARGMAPTPOLB | |
| SCHEMBL6213639 | 0.85 | ALDH1A1 (0.52) | MMP13MAPTRXFP1KDM4EKDR | |
| SCHEMBL6212989 | 0.83 | MMP13 (0.54) | MMP13PPARGPTGER4MAPTRXFP1 | |
| SCHEMBL6214058 | 0.83 | MMP13 (0.54) | MMP13PPARGPTGER4MAPTRXFP1 | |
| SCHEMBL6213923 | 0.82 | MMP13 (0.54) | MMP13PPARGMAPTRXFP1POLB | |
| SCHEMBL6214009 | 0.82 | PPARG (0.46) | MMP13PPARGMAPTRXFP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1362048-B1 | TRIAZOLO COMPOUNDS AS MMP INHIBITORS | WARNER LAMBERT CO (US) | 2005-05-04 | — | — | EP | claimed |
| US-6849637-B2 | Triazolo compounds as MMP inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-02-01 | — | — | US | claimed |
| US-20020151558-A1 | Triazolo compounds as MMP inhibitors | ANDRIANJARA CHARLES (FR) | 2002-10-17 | — | — | US | claimed |
| US-6849637-B2 | Triazolo compounds as MMP inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-02-01 | — | — | US | disclosed |
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | ANDRIANJARA CHARLES (FR) | 2005-01-06 | — | — | US | disclosed |
| US-20040034085-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-02-19 | — | — | US | disclosed |
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| US-20020151558-A1 | Triazolo compounds as MMP inhibitors | ANDRIANJARA CHARLES (FR) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | MMP13, MMP12, MMP25 | MMP13 1/4885PPARG 1806/4885PTGER4 706/4885 |
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | MMP13, MMP11, MMP10 | MMP13 1/4885PPARG 497/4885PTGER4 401/4885 |
| US-20020151558-A1 | Triazolo compounds as MMP inhibitors | MMP8, MMP13, MMP9 | MMP13 2/4885PPARG 3314/4885PTGER4 567/4885 |
| US-20040034085-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | MMP11, MMP13, MMP10 | MMP13 2/4885PPARG 891/4885PTGER4 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.